ADAG News and Press, Adagene Inc. From 03/16/22

Adagene (NASDAQ:ADAG) said it received FDA clearance to proceed with a phase 1b/2 trial of ADG126, in combination with the Merck's (NYSE:MRK) Keytruda (pembrolizumab) in solid tumors. The global trial (ADG126-P001 / KEYNOTE-C98) will evaluate patients with advanced/metastatic solid tumor...

– ADG126-P001 trial being initiated at multiple sites in U.S. and Asia Pacific – – First SAFEbody candidate to advance into combination clinical trial, building on strong single-agent clinical profile – SAN DIEGO and SUZHOU, China, Mar...

- New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company’s AI-powered platform - - SAFEbody® precision masking technology integrated across antibody-based modalities in...

Suzhou antibody company Adagene will apply its masking technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights (ex-Japan) for two Heidelberg Pharma ADC candidates with options on two more in a deal potentia...

The ADRs of Adagene (NASDAQ:ADAG) have climbed ~17% in the pre-market Tuesday after the China-based clinical-stage biopharmaceutical company announced a partnership with Frech pharma giant Sanofi (NASDAQ:SNY) for the development and commercialization of certain immuno-oncology drugs...

- Total potential transaction value of $2.5 billion plus royalties - SAN DIEGO and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announc...

SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company’s management will participate in o...

SAN DIEGO and SUZHOU, China, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced board and management appointments aimed at supporting the company’s ...

SAN DIEGO and SUZHOU, China, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the first patient has been dosed in a combination cohort of its anti-...

- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development- SAN DIEGO and SUZHOU, China, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“...